Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAalborg University Hospital
About this trial
The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.
Eligibility criteria
Qualifiers
Patients > 18 years
Diagnosed with RA, PsA or AS.
Starting treatment with infliximab or adalimumab.
Co- treatment with csDMARD or glucocorticoid is acceptable.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
120 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov